India
· Delayed Price · Currency is INR Marksans Pharma Statistics
Total Valuation
Marksans Pharma has a market cap or net worth of INR 102.44 billion. The enterprise value is 97.94 billion.
| Market Cap | 102.44B |
| Enterprise Value | 97.94B |
Important Dates
The last earnings date was Tuesday, February 11, 2025.
| Earnings Date | Feb 11, 2025 |
| Ex-Dividend Date | Sep 17, 2024 |
Share Statistics
Marksans Pharma has 453.16 million shares outstanding. The number of shares has increased by 0.41% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 453.16M |
| Shares Change (YoY) | +0.41% |
| Shares Change (QoQ) | -0.31% |
| Owned by Insiders (%) | 43.87% |
| Owned by Institutions (%) | 12.65% |
| Float | 204.19M |
Valuation Ratios
The trailing PE ratio is 27.80 and the forward PE ratio is 22.25. Marksans Pharma's PEG ratio is 0.93.
| PE Ratio | 27.80 |
| Forward PE | 22.25 |
| PS Ratio | 4.14 |
| PB Ratio | 4.50 |
| P/TBV Ratio | 4.72 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 0.93 |
Enterprise Valuation
| EV / Earnings | 26.59 |
| EV / Sales | 3.96 |
| EV / EBITDA | 18.93 |
| EV / EBIT | 22.73 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 0.38 |
| Debt / FCF | n/a |
| Interest Coverage | 32.97 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 11.94% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 21.69M |
| Profits Per Employee | 3.23M |
| Employee Count | 1,141 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +41.64% in the last 52 weeks. The beta is 1.66, so Marksans Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.66 |
| 52-Week Price Change | +41.64% |
| 50-Day Moving Average | 266.98 |
| 200-Day Moving Average | 244.87 |
| Relative Strength Index (RSI) | 37.41 |
| Average Volume (20 Days) | 1,277,633 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Marksans Pharma had revenue of INR 24.74 billion and earned 3.68 billion in profits. Earnings per share was 8.13.
| Revenue | 24.74B |
| Gross Profit | 13.55B |
| Operating Income | 4.31B |
| Pretax Income | 4.88B |
| Net Income | 3.68B |
| EBITDA | 4.93B |
| EBIT | 4.31B |
| Earnings Per Share (EPS) | 8.13 |
Balance Sheet
The company has 6.72 billion in cash and 1.98 billion in debt, giving a net cash position of 4.74 billion or 10.45 per share.
| Cash & Cash Equivalents | 6.72B |
| Total Debt | 1.98B |
| Net Cash | 4.74B |
| Net Cash Per Share | 10.45 |
| Equity (Book Value) | 23.05B |
| Book Value Per Share | 50.24 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 54.76%, with operating and profit margins of 17.41% and 14.89%.
| Gross Margin | 54.76% |
| Operating Margin | 17.41% |
| Pretax Margin | 19.73% |
| Profit Margin | 14.89% |
| EBITDA Margin | 19.92% |
| EBIT Margin | 17.41% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.60, which amounts to a dividend yield of 0.27%.
| Dividend Per Share | 0.60 |
| Dividend Yield | 0.27% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | n/a |
| Buyback Yield | -0.41% |
| Shareholder Yield | -0.14% |
| Earnings Yield | 3.60% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |